{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:06:23Z","timestamp":1790892383282,"version":"4.1.0"},"reference-count":260,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014597","name":"LAM Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014597","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.drudis.2025.104496","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:40:35Z","timestamp":1760064035000},"page":"104496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic strategies targeting ocular vasculopathies: Current advances and emerging challenges"],"prefix":"10.1016","volume":"30","author":[{"given":"Julie","family":"Le Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-5940","authenticated-orcid":false,"given":"Cyril","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104496_b0005","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1210\/jcem.84.10.6025","article-title":"The vascular endothelial growth factor\/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy","volume":"84","author":"Otani","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.drudis.2025.104496_b0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1087-0024.2000.00014.x","article-title":"Angiogenesis in wound healing","volume":"5","author":"Tonnesen","year":"2000","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.drudis.2025.104496_b0015","first-page":"H679","article-title":"Exercise-induced expression of angiogenesis-related transcription and growth factors in human skeletal muscle","volume":"276","author":"Gustafsson","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.drudis.2025.104496_b0020","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0002-9440(10)61231-X","article-title":"Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function","volume":"167","author":"Marneros","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2025.104496_b0025","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104496_b0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3727\/096504014X13890370410285","article-title":"Inhibition of tumor angiogenesis by interferon-\u03b3 by suppression of tumor-associated macrophage differentiation","volume":"21","author":"Sun","year":"2014","journal-title":"Oncol Res"},{"key":"10.1016\/j.drudis.2025.104496_b0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/scbi.1996.0019","article-title":"Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology","volume":"7","author":"Jendraschak","year":"1996","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.drudis.2025.104496_b0040","doi-asserted-by":"crossref","first-page":"11142","DOI":"10.1038\/s41598-018-29465-9","article-title":"Pigment epithelium-derived factor (PEDF) as a regulator of wound angiogenesis","volume":"8","author":"Michalczyk","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104496_b0045","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104496_b0050","series-title":"The Eye: Basic Sciences in Practice","author":"Forrester","year":"2016"},{"key":"10.1016\/j.drudis.2025.104496_b0055","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/jov.20.12.2","article-title":"A review of interactions between peripheral and foveal vision","volume":"20","author":"Stewart","year":"2020","journal-title":"J Vis"},{"key":"10.1016\/j.drudis.2025.104496_b0060","series-title":"Ocular Transporters and Receptors","first-page":"1","article-title":"Eye: anatomy, physiology and barriers to drug delivery","author":"Cholkar","year":"2013"},{"key":"10.1016\/j.drudis.2025.104496_b0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/156652410791065336","article-title":"PEDF in angiogenic eye diseases","volume":"10","author":"Tombran-Tink","year":"2010","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.drudis.2025.104496_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/892043","article-title":"Ocular angiogenesis","volume":"2015","author":"Dreyfuss","year":"2015","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0075","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3390\/cells10051049","article-title":"Anti-VEGF-resistant retinal diseases: a review of the latest treatment options","volume":"10","author":"Wallsh","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2025.104496_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/317536","article-title":"Age-related macular degeneration: pathogenesis, genetic background, and the role of nutritional supplements","volume":"2014","author":"Moschos","year":"2014","journal-title":"J Chem"},{"key":"10.1016\/j.drudis.2025.104496_b0085","first-page":"74","article-title":"Age-related macular degeneration","volume":"59","author":"Gheorghe","year":"2015","journal-title":"Rom J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0090","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1167\/iovs.07-0526","article-title":"Foveolar choroidal circulation and choroidal neovascularization in age-related macular degeneration","volume":"49","author":"Metelitsina","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2025.104496_b0095","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.drudis.2025.104496_b0100","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/07853890600946724","article-title":"Age\u2010related macular degeneration\u2014emerging pathogenetic and therapeutic concepts","volume":"38","author":"Gehrs","year":"2006","journal-title":"Ann Med"},{"key":"10.1016\/j.drudis.2025.104496_b0105","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2415-10-31","article-title":"Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis","volume":"10","author":"Chakravarthy","year":"2010","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0115","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/archopht.119.10.1455","article-title":"Risk factors for age-related maculopathy: the Visual Impairment Project","volume":"119","author":"McCarty","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0120","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1001\/archophthalmol.2009.130","article-title":"Association between dietary fat intake and age-related macular degeneration in the Carotenoids in Age-Related Eye Disease Study (CAREDS): an ancillary study of the Women\u2019s Health Initiative","volume":"127","author":"Parekh","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/archopht.123.3.321","article-title":"The US Twin study of age-related macular degeneration: relative roles of genetic and environmental influences","volume":"123","author":"Seddon","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0130","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0161-6420(85)33819-8","article-title":"Clinical applications of the organic dye laser","volume":"92","author":"L\u2019Esperance","year":"1985","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0135","unstructured":"ClinicalTrials.gov. Study Details | Macular Photocoagulation Study (MPS). Published June 2002. Updated 24 June 2005. Accessed 13 May 2024. https:\/\/clinicaltrials.gov\/study\/NCT00000158."},{"key":"10.1016\/j.drudis.2025.104496_b0140","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.3390\/molecules27165089","article-title":"Recent advances in age-related macular degeneration therapies","volume":"27","author":"Fabre","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2025.104496_b0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/cancers8090083","article-title":"Prospects in the application of photodynamic therapy in oral cancer and premalignant lesions","volume":"8","author":"Saini","year":"2016","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104496_b0150","unstructured":"VISUDYNE. Published 21 March 2016. Accessed 23 May 2024. https:\/\/www.has-sante.fr\/jcms\/c_2613515\/fr\/visudyne-verteporfine."},{"key":"10.1016\/j.drudis.2025.104496_b0155","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archopht.117.9.1177","article-title":"Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study","volume":"117","author":"Schmidt-Erfurth","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0002-9394(03)00223-X","article-title":"Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1","volume":"136","author":"Blinder","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0165","unstructured":"Place dans la strat\u00e9gie th\u00e9rapeutique de LUCENTIS (ranibizumab), EYLEA (aflibercept) et de leurs comparateurs cliniquement pertinents dans la forme n\u00e9ovasculaire (humide) de la DMLA. Published 25 October 2017. Accessed 23 May 2024. https:\/\/www.has-sante.fr\/jcms\/c_2800955\/fr\/place-dans-la-strategie-therapeutique-de-lucentis-ranibizumab-eylea-aflibercept-et-de-leurs-comparateurs-cliniquement-pertinents-dans-la-forme-neovasculaire-humide-de-la-dmla."},{"key":"10.1016\/j.drudis.2025.104496_b0170","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104496_b0175","unstructured":"Genentech, Inc. A phase III, multicenter, randomized, double masked, active treatment-controlled study of the efficacy and safety of rhuFab V2 (ranibizumab) compared with verteporfin (Visudyne) photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration. Updated 18 March 2014. Accessed 16 May 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT00061594."},{"key":"10.1016\/j.drudis.2025.104496_b0180","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","article-title":"Clinical pharmacology of intravitreal anti-VEGF drugs","volume":"32","author":"Fogli","year":"2018","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2025.104496_b0185","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1016\/j.drudis.2025.104496_b0190","unstructured":"Regeneron Pharmaceuticals. Vascular endothelial growth factor VEGF trap-eye:investigation of efficacy and safety in wet age-related macular degeneration (AMD) (VIEW1). Updated 20 December 2012. Accessed 27 May 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT00509795."},{"key":"10.1016\/j.drudis.2025.104496_b0195","unstructured":"Bayer. A randomized, double masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF trap in subjects with neovascular age-related macular degeneration (AMD). Updated 28 November 2014. Accessed 19 May 2024. https:\/\/clinicaltrials.gov\/study\/NCT00637377?a=9."},{"key":"10.1016\/j.drudis.2025.104496_b0200","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0205","unstructured":"Alcon Research. A two-year, randomized, double-masked, multicenter, two-arm study comparing the efficacy and safety of RTH258 6 mg versus aflibercept in subjects with neovascular age-related macular degeneration. Updated 9 September 2020. Accessed 27 May 2024. https:\/\/clinicaltrials.gov\/study\/NCT02434328?cond=NCT02434328&rank=1."},{"key":"10.1016\/j.drudis.2025.104496_b0210","unstructured":"Alcon Research. A two-year, randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration. Updated 8 January 2020. Accessed 27 May 2024. https:\/\/clinicaltrials.gov\/study\/NCT02307682?cond=NCT02307682&rank=1."},{"key":"10.1016\/j.drudis.2025.104496_b0215","unstructured":"Hoffmann-La Roche. A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with neovascular age-related macular degeneration (TENAYA). Updated 16 January 2023. Accessed 6 May 2024. https:\/\/clinicaltrials.gov\/study\/NCT03823287."},{"key":"10.1016\/j.drudis.2025.104496_b0220","unstructured":"Hoffmann-La Roche. A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with neovascular age-related macular degeneration (LUCERNE). Updated 16 December 2022. Accessed 16 May 2024. https:\/\/clinicaltrials.gov\/study\/NCT03823300."},{"key":"10.1016\/j.drudis.2025.104496_b0225","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/jcm4020343","article-title":"Age-related macular degeneration: advances in management and diagnosis","volume":"4","author":"Yonekawa","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2025.104496_b0230","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Comparison of Age-related Macular Degeneration Treatments Trials Research Group","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0235","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Comparison of Age-related Macular Degeneration Treatments Trials Research Group","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0240","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104496_b0245","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.ophtha.2006.02.027","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials","volume":"113","author":"Inhibition Study","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0250","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology","volume":"126","author":"Bakri","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0255","unstructured":"Chengdu Kanghong Biotech Co Ltd. A multicenter, double-masked, randomized, dose-ranging trial to evaluate the efficacy and safety of conbercept intravitreal injection in subjects with neovascular age-related macular degeneration (AMD) (PANDA-1). Updated 24 June 2021. Accessed 19 May 2024. https:\/\/clinicaltrials.gov\/study\/NCT03577899?cond=NCT03577899&rank=1."},{"key":"10.1016\/j.drudis.2025.104496_b0260","unstructured":"Chengdu Kanghong Biotech Co Ltd. A multicenter, double-masked, randomized, dose-ranging trial to evaluate the efficacy and safety of conbercept intravitreal injection in subjects with neovascular age-related macular degeneration (AMD) (PANDA-2). Updated 22 June 2021. Accessed 12 May 2024. https:\/\/clinicaltrials.gov\/study\/NCT03630952?cond=NCT03630952&rank=1."},{"key":"10.1016\/j.drudis.2025.104496_b0265","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1358\/dot.2020.56.5.3137164","article-title":"An update on conbercept to treat wet age-related maculardegeneration","volume":"56","author":"Ferro Desideri","year":"2020","journal-title":"Drugs Today"},{"key":"10.1016\/j.drudis.2025.104496_b0270","unstructured":"Krader CG. Novel anti-VEGF agent approved in China may reduce injection frequency. Published 1 April 2015. Accessed 16 May 2024. https:\/\/www.ophthalmologytimes.com\/view\/novel-anti-vegf-agent-approved-china-may-reduce-injection-frequency."},{"key":"10.1016\/j.drudis.2025.104496_b0275","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41433-019-0607-8","article-title":"Abicipar pegol: the non-monoclonal antibody anti-VEGF","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.drudis.2025.104496_b0280","unstructured":"Allergan. Safety and efficacy of abicipar pegol (AGN-150998) in patients with neovascular age-related macular degeneration (SEQUOIA study). Updated 17 July 2020. Accessed 17 May 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT02462486."},{"key":"10.1016\/j.drudis.2025.104496_b0285","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ophtha.2020.11.017","article-title":"Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration","volume":"128","author":"Khurana","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0290","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2023.02.001","article-title":"A randomized controlled trial of OPT-302, a VEGF-C\/D inhibitor for neovascular age-related macular degeneration","volume":"130","author":"Jackson","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0295","unstructured":"Opthea Limited. A phase 1 dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of OPT-302 in combination with ranibizumab in subjects with wet AMD. Updated 2 November 2017. Accessed 2 June 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT02543229?cond=NCT02543229&rank=1."},{"key":"10.1016\/j.drudis.2025.104496_b0300","unstructured":"Opthea Limited. A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD). Updated 8 January 2021. Accessed 3 June 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT03345082?cond=NCT03345082&rank=1."},{"key":"10.1016\/j.drudis.2025.104496_b0305","unstructured":"Opthea Limited. A phase 3, multicentre, double-masked, randomised study to evaluate the efficacy and safety of intravitreal OPT-302 in combination with aflibercept, compared with aflibercept alone, in participants with nAMD. Updated 26 March 2024. Accessed 29 May 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT04757636?cond=NCT04757636&rank=1."},{"key":"10.1016\/j.drudis.2025.104496_b0310","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jamaophthalmol.2013.5002","article-title":"Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration","volume":"131","author":"McLaughlin","year":"2013","journal-title":"JAMA Ophth"},{"key":"10.1016\/j.drudis.2025.104496_b0315","unstructured":"GlaxoSmithKline. An open-label, phase 2a study to evaluate pazopanib eye drops administered for 12 weeks to patients with neovascular age-related macular degeneration. Updated 23 August 2017. Accessed 17 May 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT01362348?cond=NCT01362348&rank=1."},{"key":"10.1016\/j.drudis.2025.104496_b0320","unstructured":"Roizman K, Rudolf M. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents. 2018. Patent Application US20180296525A1."},{"key":"10.1016\/j.drudis.2025.104496_b0325","unstructured":"PanOptica, Inc. A phase I open-label, multi-center trial with randomization to dose to evaluate the safety and tolerability of topical ocular PAN-90806 in patients with neovascular age-related macular degeneration (AMD). Updated 27 September 2016. Accessed 2 June 2024. https:\/\/clinicaltrials.gov\/study\/NCT02022540."},{"key":"10.1016\/j.drudis.2025.104496_b0330","unstructured":"PanOptica, Inc. A randomized, double masked, uncontrolled, multicenter phase I\/II study to evaluate safety and tolerability of PAN-90806 eye drops, suspension in treatment-na\u00efve participants with neovascular age-related macular degeneration (AMD). Updated 8 July 2019. Accessed 3 June 2024. https:\/\/clinicaltrials.gov\/study\/NCT03479372."},{"key":"10.1016\/j.drudis.2025.104496_b0335","doi-asserted-by":"crossref","first-page":"20887","DOI":"10.3390\/molecules201119735","article-title":"Quaternary alkylammonium conjugates of steroids: synthesis, molecular structure, and biological studies","volume":"20","author":"Brycki","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2025.104496_b0340","unstructured":"Ohr Pharmaceutical Inc. Phase II study of the efficacy and safety of squalamine lactate ophthalmic formulation 0.2% BID in subjects with neovascular AMD. Updated 11 June 2015. Accessed 4 June 2024. https:\/\/clinicaltrials.gov\/study\/NCT01678963?cond=NCT01678963&rank=1."},{"key":"10.1016\/j.drudis.2025.104496_b0345","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14728214.2019.1604684","article-title":"Emerging PEGylated non-biologic drugs","volume":"24","author":"Park","year":"2019","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.drudis.2025.104496_b0350","unstructured":"Ophthotech Corporation. A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista\u00ae (anti PDGF-B pegylated aptamer) administered in combination with Lucentis\u00ae compared to Lucentis\u00ae monotherapy in subjects with subfoveal neovascular age-related macular degeneration. Updated 20 February 2024. Accessed 1 June 2024. https:\/\/clinicaltrials.gov\/study\/NCT01940900?cond=NCT01940900&rank=1."},{"key":"10.1016\/j.drudis.2025.104496_b0355","unstructured":"APM news. DMLA: deux \u00e9tudes de phase III n\u00e9gatives avec le pegpleranib. Published 12 December 2016. Accessed 1 September 2025. https:\/\/www.apmnews.com:443\/story.php?objet=296301."},{"key":"10.1016\/j.drudis.2025.104496_b0360","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1051\/medsci\/2023177","article-title":"Traitement topique de la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge \u2013 O\u00f9 en sommes-nous?","volume":"39","author":"Pierre","year":"2023","journal-title":"Med Sci (Paris)"},{"key":"10.1016\/j.drudis.2025.104496_b0365","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4239\/wjd.v6.i2.312","article-title":"Current knowledge on diabetic retinopathy from human donor tissues","volume":"6","author":"Eisma","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1016\/j.drudis.2025.104496_b0370","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.pop.2015.05.005","article-title":"Diabetic retinopathy","volume":"42","author":"Hendrick","year":"2015","journal-title":"Prim Care"},{"key":"10.1016\/j.drudis.2025.104496_b0375","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2156273","article-title":"Diabetic macular edema pathophysiology: vasogenic versus inflammatory","volume":"2016","author":"Romero-Aroca","year":"2016","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.drudis.2025.104496_b0380","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1100\/tsw.2008.25","article-title":"Update on the treatment of diabetic retinopathy","volume":"8","author":"Wilkinson-Berka","year":"2008","journal-title":"Sci World J"},{"key":"10.1016\/j.drudis.2025.104496_b0385","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-8587(19)30411-5","article-title":"Screening for diabetic retinopathy: new perspectives and challenges","author":"Vujosevic","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.drudis.2025.104496_b0390","first-page":"3","article-title":"Diabetic retinopathy in the Asia-Pacific","volume":"7","author":"Chua","year":"2018","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.drudis.2025.104496_b0395","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11892-014-0515-z","article-title":"Genetics of diabetic retinopathy","volume":"14","author":"Cho","year":"2014","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.drudis.2025.104496_b0400","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2337\/diab.31.1.19","article-title":"Diabetic retinopathy in identical twins","volume":"31","author":"Leslie","year":"1982","journal-title":"Diabetes"},{"key":"10.1016\/j.drudis.2025.104496_b0405","series-title":"Surgical Retina: ESASO Modules 2009 and 2010: Selected Contributions","article-title":"Diabetic retinopathy management","author":"Zarbin","year":"2012"},{"key":"10.1016\/j.drudis.2025.104496_b0410","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jama.298.8.902","article-title":"Management of diabetic retinopathy: a systematic review","volume":"298","author":"Mohamed","year":"2007","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.drudis.2025.104496_b0415","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0161-6420(03)00579-7","article-title":"The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study","volume":"110","author":"Chew","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0420","article-title":"Recent advances in the treatment and delivery system of diabetic retinopathy","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.drudis.2025.104496_b0425","unstructured":"WHO. Diabetes. Accessed 25 May 2024. https:\/\/www.who.int\/health-topics\/diabetes."},{"key":"10.1016\/j.drudis.2025.104496_b0430","unstructured":"NIDDK. Symptoms & causes of diabetes \u2013 NIDDK. Updated October 2024. Accessed 5 May 2024. https:\/\/www.niddk.nih.gov\/health-information\/diabetes\/overview\/symptoms-causes."},{"key":"10.1016\/j.drudis.2025.104496_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.drudis.2025.104496_b0440","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.drudis.2025.104496_b0445","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.drudis.2025.104496_b0450","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S2213-8587(16)30052-3","article-title":"Diabetic macular oedema","volume":"5","author":"Tan","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.drudis.2025.104496_b0455","series-title":"Clinical Strategies in the Management of Diabetic Retinopathy","first-page":"97","article-title":"Diabetic macular edema","author":"Bandello","year":"2019"},{"key":"10.1016\/j.drudis.2025.104496_b0460","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","article-title":"Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales","volume":"110","author":"Wilkinson","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0465","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2013.02.001","article-title":"Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions","volume":"34","author":"Klaassen","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.drudis.2025.104496_b0470","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","article-title":"Prevalence of and risk factors for diabetic macular edema in the United States","volume":"132","author":"Varma","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0475","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1056\/NEJM200002103420603","article-title":"Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy","volume":"342","author":"Diabetes","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104496_b0480","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1167\/iovs.13-11849","article-title":"Quantitative measurement of hard exudates in patients with diabetes and their associations with serum lipid levels","volume":"54","author":"Sasaki","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2025.104496_b0485","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye Vis (lond)"},{"key":"10.1016\/j.drudis.2025.104496_b0490","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ophtha.2006.08.053","article-title":"Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography","volume":"114","author":"Kim","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0495","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104496_b0500","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104496_b0505","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3390\/medicina59071319","article-title":"The role of laser photocoagulation in treating diabetic macular edema in the era of intravitreal drug administration: a descriptive review","volume":"59","author":"Nozaki","year":"2023","journal-title":"Medicina"},{"key":"10.1016\/j.drudis.2025.104496_b0510","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group","volume":"103","author":"Photocoagulation for diabetic macular edema","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0515","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1167\/iovs.14-14682","article-title":"The effect of photocoagulation in ischemic areas to prevent recurrence of diabetic macular edema after intravitreal bevacizumab injection","volume":"55","author":"Takamura","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2025.104496_b0520","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0161-6420(92)31901-3","article-title":"Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction","volume":"99","author":"Lewis","year":"1992","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0525","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/eye.2008.84","article-title":"Vitrectomy for diabetic macular oedema","volume":"22","author":"Laidlaw","year":"2008","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.drudis.2025.104496_b0530","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0535","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s10792-021-01712-5","article-title":"Long-term full-field and multifocal electroretinographic changes after treatment with ranibizumab in patients with diabetic macular edema","volume":"41","author":"Yigit","year":"2021","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0540","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamaophthalmol.2017.0455","article-title":"Vascular safety of ranibizumab in patients with diabetic macular edema: a pooled analysis of patient-level data from randomized clinical trials","volume":"135","author":"Zarbin","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0545","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0550","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0555","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104496_b0560","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0565","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamaophthalmol.2023.5248","article-title":"Efficacy and safety of brolucizumab for diabetic macular edema: the KINGFISHER randomized clinical trial","volume":"141","author":"Singh","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0570","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104496_b0575","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1167\/iovs.64.13.31","article-title":"Turnover of microaneurysms after intravitreal injections of faricimab for diabetic macular edema","volume":"64","author":"Takamura","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2025.104496_b0580","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0585","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"The Diabetic Retinopathy Clinical Research Network","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104496_b0590","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0002-9394(01)01269-7","article-title":"Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema","volume":"133","author":"Funatsu","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0595","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0600","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ophtha.2019.10.005","article-title":"A collaborative retrospective study on the efficacy and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: the European DME registry study","volume":"127","author":"Rosenblatt","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0605","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40123-018-0155-5","article-title":"The USER study: a chart review of patients receiving a 0.2 \u00b5g\/day fluocinolone acetonide implant for diabetic macular edema","volume":"8","author":"Eaton","year":"2019","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.drudis.2025.104496_b0610","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0615","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ophtha.2022.01.015","article-title":"Three-year safety and efficacy of the 0.19-mg fluocinolone acetonide intravitreal implant for diabetic macular edema: the PALADIN study","volume":"129","author":"Singer","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0620","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1177\/11206721221080288","article-title":"Fluocinolone acetonide implant in diabetic macular edema: international experts\u2019 panel consensus guidelines and treatment algorithm","volume":"32","author":"Kodjikian","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0625","doi-asserted-by":"crossref","first-page":"45","DOI":"10.17219\/acem\/29849","article-title":"The effects and safety of intravitreal triamcinolone injections in the treatment of diabetic macular edema","volume":"26","author":"Zaj\u0105c-Pytrus","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.drudis.2025.104496_b0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/erj.erj_15_20","article-title":"Efficacy of posterior Sub-Tenon\u2019s capsule injection compared to intravitreal injection of triamcinolone acetonide for treatment of diabetic macular edema: a systematic review and meta-analysis","volume":"8","author":"Ibrahim","year":"2021","journal-title":"Egypt Retina J"},{"key":"10.1016\/j.drudis.2025.104496_b0635","unstructured":"ClinicalTrials.gov. Study Details | Safety and efficacy study of Conbercept in diabetic macular edema (DME) (sailing). Published June 2015. Updated 6 January 2016. Accessed 24 May 2024. https:\/\/clinicaltrials.gov\/study\/NCT02194634?cond=%20Safety%20and%20Efficacy%20Study%20of%20Conbercept%20in%20Diabetic%20Macular%20Edema%20(DME)%20(Sailing)&rank=1."},{"key":"10.1016\/j.drudis.2025.104496_b0640","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/bjophthalmol-2020-318690","article-title":"Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study","volume":"106","author":"Liu","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0645","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5809081","article-title":"Comparison of the efficacy and safety of intravitreal conbercept with intravitreal ranibizumab for treatment of diabetic macular edema: a meta-analysis","volume":"2020","author":"Sun","year":"2020","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0650","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.750132","article-title":"Cost-effectiveness of conbercept vs. ranibizumab for age-related macular degeneration, diabetic macular edema, and pathological myopia: population-based cohort study and Markov model","volume":"8","author":"Cui","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.drudis.2025.104496_b0655","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s13300-020-00806-0","article-title":"One-year effectiveness study of intravitreously administered Conbercept\u00ae monotherapy in diabetic macular degeneration: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.drudis.2025.104496_b0660","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021992","article-title":"Evaluation of the efficacy of Conbercept in the treatment of diabetic macular edema based on OCTA","volume":"99","author":"Ba","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.drudis.2025.104496_b0665","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ajo.2012.09.032","article-title":"Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I\/II study","volume":"155","author":"Campochiaro","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0670","unstructured":"Molecular Partners. Abicipar Pegol PALM study phase 2 data in diabetic macular edema (DME) oresented at 2016 AAO Annual Meeting. Published 15 October 2016. Accessed 8 June 2024. https:\/\/www.molecularpartners.com\/abicipar-pegol-palm-study-phase-2-data-in-diabetic-macular-edema-dme-presented-at-2016-aao-annual-meeting\/."},{"key":"10.1016\/j.drudis.2025.104496_b0675","unstructured":"Molecular Partners. Allergan and molecular partners announce two positive phase 3 clinical trials for abicipar pegol 8 and 12-week regimens for the treatment in patients with neovascular age-related macular degeneration. Published 19 July 2018. Accessed 27 May 2024. https:\/\/investors.molecularpartners.com\/news-releases\/news-release-details\/allergan-and-molecular-partners-announce-two-positive-phase-3\/."},{"key":"10.1016\/j.drudis.2025.104496_b0680","unstructured":"Opthea Limited. A dose ranging study of OPT-302 with aflibercept for persistent diabetic macular edema. Updated 30 May 2022. Accessed 3 June 2024. https:\/\/clinicaltrials.gov\/study\/NCT03397264."},{"key":"10.1016\/j.drudis.2025.104496_b0685","first-page":"3670","article-title":"Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate with extended durability","volume":"60","author":"Patel","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2025.104496_b0690","unstructured":"Kodiak Sciences Inc. A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) Published 22 August 2024. https:\/\/clinicaltrials.gov\/study\/NCT04611152."},{"key":"10.1016\/j.drudis.2025.104496_b0695","unstructured":"KODIAK. Kodiak sciences announces topline results from its phase 3 studies of tarcocimab tedromer in neovascular age-related macular degeneration and diabetic macular edema and provides update on tarcocimab development program. Published 24 July 2023. Accessed 25 May 2024. https:\/\/ir.kodiak.com\/news-releases\/news-release-details\/kodiak-sciences-announces-topline-results-its-phase-3-studies\/."},{"key":"10.1016\/j.drudis.2025.104496_b0700","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.exer.2014.11.004","article-title":"Therapeutic efficacy of a novel non-peptide \u03b1v\u03b23 integrin antagonist for pathological retinal angiogenesis in mice","volume":"129","author":"Li","year":"2014","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.drudis.2025.104496_b0705","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1172\/JCI74527","article-title":"Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature","volume":"124","author":"Shen","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104496_b0710","unstructured":"Aerpio Therapeutics. Phase 1b\/2a open label, multiple-ascending dose cohort study to assess the safety, tolerability, pilot efficacy, pharmacokinetics and pharmacodynamic effects of 28 day repeat subcutaneous doses of AKB-9778 in subjects with diabetic macular edema. Updated 9 March 2015. Accessed 16 May 2024. https:\/\/clinicaltrials.gov\/study\/NCT01702441."},{"key":"10.1016\/j.drudis.2025.104496_b0715","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ophtha.2014.09.023","article-title":"Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2","volume":"122","author":"Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0720","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.ophtha.2016.04.025","article-title":"Enhanced benefit in diabetic macular edema from AKB-9778 Tie2 activation combined with vascular endothelial growth factor suppression","volume":"123","author":"Campochiaro","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0725","first-page":"307","article-title":"Nonclinical safety and pharmacology of RZ402, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema as a daily oral therapy","volume":"61","author":"Mantripragada","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2025.104496_b0730","unstructured":"REZOLUTE. Rezolute reports positive topline results from phase 2 proof of concept study of RZ402 in patients with diabetic macular edema (DME). Published 21 May 2024. Accessed 1 June 2024. https:\/\/ir.rezolutebio.com\/news-events\/press-releases\/detail\/330\/rezolute-reports-positive-topline-results-from-phase-2."},{"key":"10.1016\/j.drudis.2025.104496_b0735","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.ophtha.2010.01.058","article-title":"Natural history of branch retinal vein occlusion: an evidence-based systematic review","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0740","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(14)70001-7","article-title":"Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics","volume":"117","author":"Hayreh","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0745","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0750","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archopht.126.4.513","article-title":"The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study","volume":"126","author":"Klein","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0755","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","article-title":"Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study","volume":"114","author":"Mitchell","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0760","unstructured":"The Royal College of Ophthalmologists. Retinal vein occlusion (RVO) guidelines. Published July 2015. Accessed 16 May 2024. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2021\/08\/Retinal-Vein-Occlusion-RVO-Guidelines-July-2015.pdf."},{"key":"10.1016\/j.drudis.2025.104496_b0765","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1445-5994.2008.01720.x","article-title":"Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management","volume":"38","author":"Yau","year":"2008","journal-title":"Intern Med J"},{"key":"10.1016\/j.drudis.2025.104496_b0770","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/13543776.2019.1671353","article-title":"Agents for the prevention and treatment of age-related macular degeneration and macular edema: a literature and patent review","volume":"29","author":"Supuran","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.drudis.2025.104496_b0775","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.3390\/jcm10225300","article-title":"Treatment of macular edema in vascular retinal diseases: a 2021 update","volume":"10","author":"Grzybowski","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.drudis.2025.104496_b0780","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.12688\/f1000research.19198.1","article-title":"Emerging therapies in the management of macular edema: a review","volume":"8","author":"Sacconi","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.drudis.2025.104496_b0785","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/eye.2011.92","article-title":"The burden of disease of retinal vein occlusion: review of the literature","volume":"25","author":"Laouri","year":"2011","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2025.104496_b0790","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","article-title":"Natural history of central retinal vein occlusion: an evidence-based systematic review","volume":"117","author":"McIntosh","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0795","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/archopht.124.5.726","article-title":"Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study","volume":"124","author":"Cugati","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0800","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0161-6420(92)31940-2","article-title":"Risk factors for retinal vein occlusions. A case-control study","volume":"99","author":"Rath","year":"1992","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0805","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ophtha.2004.10.039","article-title":"Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies","volume":"112","author":"Wong","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0810","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0002-9394(84)90316-7","article-title":"Argon laser photocoagulation for macular edema in branch vein occlusion","volume":"98","author":"Group TBVOS","year":"1984","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0815","doi-asserted-by":"crossref","unstructured":"Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology. 1995;102:1425\u20131433. https:\/\/doi.org\/10.1016\/s0161-6420(95)30849-4.","DOI":"10.1016\/S0161-6420(95)30849-4"},{"key":"10.1016\/j.drudis.2025.104496_b0820","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0825","unstructured":"Genentech, Inc. A study evaluating dosing regimens for treatment with intravitreal ranibizumab injections in subjects with macular edema following retinal vein occlusion. Updated 27 March 2014. Accessed 23 May 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT01277302?tab=history."},{"key":"10.1016\/j.drudis.2025.104496_b0830","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0835","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","article-title":"Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study","volume":"124","author":"Tadayoni","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0840","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ajo.2014.07.027","article-title":"Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study","volume":"158","author":"Ogura","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0845","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0850","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study","volume":"122","author":"Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0855","first-page":"1178","article-title":"Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry","volume":"106","author":"Hunt","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0860","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0865","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ceo.14225","article-title":"Management of macular oedema due to retinal vein occlusion: an evidence\u2010based systematic review and meta\u2010analysis","volume":"51","author":"Cornish","year":"2023","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0870","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta25380","article-title":"Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT","volume":"25","author":"Hykin","year":"2021","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.drudis.2025.104496_b0875","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.oret.2019.12.019","article-title":"Comparing the efficacy of bevacizumab and ranibizumab in patients with retinal vein occlusion: the bevacizumab to ranibizumab in retinal vein occlusions (BRVO) study, a randomized trial","volume":"4","author":"Vader","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.drudis.2025.104496_b0880","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archophthalmol.2009.234","volume":"127","author":"Ip","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0885","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archophthalmol.2009.233","volume":"127","author":"Scott","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0890","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0895","unstructured":"Novartis P. An eighteen-month, two-arm, randomized, double masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to macular edema secondary to branch retinal vein occlusion. Updated 27 January 2023. Accessed 3 June 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT03802630."},{"key":"10.1016\/j.drudis.2025.104496_b0900","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.bbrc.2018.12.049","article-title":"The anti-inflammatory and anti-oxidative effects of conbercept in treatment of macular edema secondary to retinal vein occlusion","volume":"508","author":"Xia","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2025.104496_b0905","article-title":"A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.drudis.2025.104496_b0910","unstructured":"Kodiak Sciences Inc. Kodiak sciences reports positive topline results from BEACON phase 3 study of tarcocimab tedromer (KSI-301) in patients with retinal vein occlusion. Published 8 August 2022. Accessed 30 May 2024. https:\/\/ir.kodiak.com\/news-releases\/news-release-details\/kodiak-sciences-reports-positive-topline-results-beacon-phase-3\/."},{"key":"10.1016\/j.drudis.2025.104496_b0915","unstructured":"Ripple Therapeutics Pty Ltd. RIPPLE-1: evaluation of safety and efficacy of the IBE-814 intravitreal implant in patients with diabetic macular oedema and macular oedema due to retinal vein occlusion. Updated 8 March 2023. Accessed 27 May 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT04576689?cond=NCT04576689&rank=1."},{"key":"10.1016\/j.drudis.2025.104496_b0920","unstructured":"Ripple Therapeutics Corporation. Ripple therapeutics announces first patient treated in phase II trial evaluating IBE-814 IVT in DME and RVO. Updated 19 April 2021. Accessed 15 May 2024. https:\/\/www.rippletherapeutics.com\/news\/ripple-therapeutics-announces-first-patient-treated-in-phase-ii-trial-evaluating-ibe-814-ivt-in."},{"key":"10.1016\/j.drudis.2025.104496_b0925","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1097\/IAE.0000000000000177","article-title":"Safety of transfoveal subthreshold diode micropulse laser for fovea-involving diabetic macular edema in eyes with good visual acuity","volume":"34","author":"Luttrull","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.drudis.2025.104496_b0930","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/1120672117750056","article-title":"Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion","volume":"28","author":"Buyru \u00d6zkurt","year":"2018","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0935","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/bjophthalmol-2019-315192","article-title":"Subthreshold laser therapy for macular oedema from branch retinal vein occlusion: focused review","volume":"104","author":"Eng","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0940","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/IAE.0000000000002165","article-title":"Combination therapy of intravitreal ranibizumab and subthreshold micropulse photocoagulation for macular edema secondary to branch retinal vein occlusion: 6-month result","volume":"39","author":"Terashima","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.drudis.2025.104496_b0945","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1089\/jop.2018.0101","article-title":"Novel triamcinolone acetonide-loaded liposomes topical formulation for the treatment of cystoid macular edema after cataract surgery: a pilot study","volume":"35","author":"Gonzalez-De la Rosa","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104496_b0950","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","article-title":"Myopia","volume":"379","author":"Morgan","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104496_b0955","unstructured":"National Eye Institute. Nearsightedness (myopia) tables. Updated December 4, 2024. Accessed May 13."},{"key":"10.1016\/j.drudis.2025.104496_b0960","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.ophtha.2006.11.034","article-title":"Morphology and long-term changes of choroidal vascular structure in highly myopic eyes with and without posterior staphyloma","volume":"114","author":"Moriyama","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b0965","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0970","doi-asserted-by":"crossref","first-page":"7532","DOI":"10.1167\/iovs.13-12795","article-title":"The economic cost of myopia in adults aged over 40 years in Singapore","volume":"54","author":"Zheng","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2025.104496_b0975","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0002-9394(81)90170-7","article-title":"Pathologic myopia and choroidal neovascularization","volume":"91","author":"Hotchkiss","year":"1981","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0980","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/bjo.87.5.570","article-title":"Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia","volume":"87","author":"Ohno-Matsui","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0985","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ajo.2015.01.022","article-title":"International photographic classification and grading system for myopic maculopathy","volume":"159","author":"Ohno-Matsui","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b0990","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.preteyeres.2012.04.001","article-title":"Choroidal neovascularization in pathological myopia","volume":"31","author":"Neelam","year":"2012","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.drudis.2025.104496_b0995","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/bjo.2005.074716","article-title":"Choroidal neovascularisation in pathological myopia: an update in management","volume":"89","author":"Chan","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1000","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/bjo.2009.163535","article-title":"Choroidal filling delay in choroidal neovascularisation due to pathological myopia","volume":"94","author":"Wakabayashi","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1005","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","article-title":"Myopic choroidal neovascularization","volume":"124","author":"Cheung","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b1010","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1167\/iovs.12-9538","article-title":"Genetic factors for choroidal neovascularization associated with high myopia","volume":"53","author":"Leveziel","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2025.104496_b1015","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1167\/iovs.13-12280","article-title":"Evaluation of pigment epithelium\u2013derived factor and complement factor I polymorphisms as a cause of choroidal neovascularization in highly myopic eyes","volume":"54","author":"Miyake","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2025.104496_b1020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ophtha.2013.06.043","article-title":"Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia","volume":"121","author":"Miyake","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b1025","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study","volume":"120","author":"Tufail","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b1030","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b1040","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal Neovascularization: the MYRROR study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b1045","unstructured":"Hoffmann-La Roche. A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with choroidal neovascularization secondary to pathologic myopia. Updated 13 May 2024. Accessed 15 May 2024. https:\/\/clinicaltrials.gov\/study\/NCT06176352."},{"key":"10.1016\/j.drudis.2025.104496_b1050","series-title":"Glaucoma: Science and Practice","author":"Morrison","year":"2003"},{"key":"10.1016\/j.drudis.2025.104496_b1055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1755-3768.1971.tb00954.x","article-title":"The frequency of rubeosis iridis in diabetic patients","volume":"49","author":"Ohrt","year":"1971","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1060","unstructured":"Shepard ZV, Hendricks TM, Boese EA, Binkley EM. Ocular ischemic syndrome in a patient with background diabetic retinopathy: distinguishing features. Published 21 March 2024. Accessed 28 May 2024. https:\/\/eyerounds.org\/cases\/356-ocular-ischemic-syndrome.htm#gsc.tab=0."},{"key":"10.1016\/j.drudis.2025.104496_b1065","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/bjo.61.4.278","article-title":"Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and neovascular glaucoma","volume":"61","author":"Laatikainen","year":"1977","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40942-016-0051-x","article-title":"Neovascular glaucoma: a review","volume":"2","author":"Rodrigues","year":"2016","journal-title":"Int J Retin Vitr"},{"key":"10.1016\/j.drudis.2025.104496_b1075","unstructured":"Salim S. Diagnosis and treatment of neovascular glaucoma. Published 7 January 2006. Accessed 7 June 2024. https:\/\/www.aao.org\/eyenet\/article\/diagnosis-treatment-of-neovascular-glaucoma."},{"key":"10.1016\/j.drudis.2025.104496_b1080","unstructured":"Yilmaz T, Cordero-Coma M, Gallagher MJ, Teasley LA. Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema. Updated 2011. Accessed 21 May 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK97959\/."},{"key":"10.1016\/j.drudis.2025.104496_b1085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0974-9233.53865","article-title":"Intravitreal bevacizumab (avastin) as an adjuvant treatment in cases of neovascular glaucoma","volume":"16","author":"Ghanem","year":"2009","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1090","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.drudis.2025.104496_b1095","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s00417-013-2428-y","article-title":"Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma\u2013results from a prospective interventional case series","volume":"251","author":"L\u00fcke","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1100","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1007\/s10792-022-02265-x","article-title":"Clinical observation of ranibizumab combined with surgery in the treatment of neovascular glaucoma with vitreous hemorrhage","volume":"42","author":"Li","year":"2022","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1105","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5632634","article-title":"Switch to aflibercept in diabetic macular edema patients unresponsive to previous anti-VEGF therapy","volume":"2017","author":"Mira","year":"2017","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1110","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1007\/s12325-020-01579-5","article-title":"Intravitreal aflibercept in Japanese patients with neovascular glaucoma: the VEGA randomized clinical trial","volume":"38","author":"Inatani","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.drudis.2025.104496_b1115","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3390\/medicina58121870","article-title":"A review of neovascular glaucoma: etiology, pathogenesis, diagnosis, and treatment","volume":"58","author":"Urbonavi\u010di\u016bt\u0117","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.drudis.2025.104496_b1120","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000431196","article-title":"Neovascular glaucoma","volume":"55","author":"Havens","year":"2016","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1125","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00417-019-04256-8","article-title":"Surgical treatment of neovascular glaucoma: a systematic review and meta-analysis","volume":"257","author":"Shchomak","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/08820530902800801","article-title":"Neovascular glaucoma: etiology, diagnosis and prognosis","volume":"24","author":"Shazly","year":"2009","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1135","first-page":"55","article-title":"Managing the painful blind eye","volume":"34","author":"Penniecook","year":"2021","journal-title":"Community Eye Health"},{"key":"10.1016\/j.drudis.2025.104496_b1140","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.canrad.2022.04.010","article-title":"La r\u00e9tinopathie radique: donn\u00e9es actuelles et perspectives","volume":"26","author":"Gilli","year":"2022","journal-title":"Cancer\/radioth\u00e9rapie"},{"key":"10.1016\/j.drudis.2025.104496_b1145","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bulcan.2018.07.011","article-title":"Prise en charge des m\u00e9lanomes oculaires, le minimum pour les oncologues","volume":"105","author":"Mathis","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.drudis.2025.104496_b1150","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/ICU.0b013e3283386687","article-title":"Classification and treatment of radiation maculopathy","volume":"21","author":"Horgan","year":"2010","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1155","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.molstruc.2012.02.070","article-title":"Synthesis, characterization and calculated non-linear optical properties of two new chalcones","volume":"1017","author":"Singh","year":"2012","journal-title":"J Mol Struct"},{"key":"10.1016\/j.drudis.2025.104496_b1160","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/IAE.0b013e31814b1b75","article-title":"Early macular morphological changes following plaque radiotherapy for uveal melanoma","volume":"28","author":"Horgan","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.drudis.2025.104496_b1165","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/S0161-6420(82)34611-4","article-title":"Radiation retinopathy","volume":"89","author":"Brown","year":"1982","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b1170","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0002-9394(98)00445-0","article-title":"Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement 1","volume":"127","author":"G\u00fcnd\u00fcz","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1175","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ijrobp.2004.07.664","article-title":"Preventing radiation retinopathy with hyperfractionation","volume":"61","author":"Monroe","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.drudis.2025.104496_b1180","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ijrobp.2007.11.043","article-title":"Bax and Bak do not exhibit functional redundancy in mediating radiation-induced endothelial apoptosis in the intestinal mucosa","volume":"70","author":"Rotolo","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.drudis.2025.104496_b1185","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.3748\/wjg.v13.i22.3043","article-title":"Radiation-induced intestinal inflammation","volume":"13","author":"Moll\u00e0","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.drudis.2025.104496_b1190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cyto.2014.08.005","article-title":"Vascular endothelial growth factor: therapeutic possibilities and challenges for the treatment of ischemia","volume":"71","author":"Crafts","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.drudis.2025.104496_b1195","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s11481-014-9531-7","article-title":"Vascular endothelial growth factor signaling in hypoxia and inflammation","volume":"9","author":"Ramakrishnan","year":"2014","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.drudis.2025.104496_b1200","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0360-3016(99)00057-7","article-title":"Late retinal complications of radiation therapy for nasal and paranasal malignancies: relationship between irradiated-dose area and severity","volume":"44","author":"Takeda","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.drudis.2025.104496_b1205","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ophtha.2014.12.034","article-title":"Early subclinical macular edema in eyes with uveal melanoma: association with future cystoid macular edema","volume":"122","author":"Mashayekhi","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b1210","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1051\/medsci\/2013294013","article-title":"Radiosensibilit\u00e9 \u2013 L\u2019\u00e9vidence d\u2019un facteur individuel","volume":"29","author":"Foray","year":"2013","journal-title":"Med Sci (Paris)"},{"key":"10.1016\/j.drudis.2025.104496_b1215","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archopht.1996.01100140299007","article-title":"Proliferative radiation retinopathy","volume":"114","author":"Kinyoun","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5301\/ejo.5000670","article-title":"Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study","volume":"26","author":"Finger","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1225","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00417-019-04347-6","article-title":"Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma","volume":"257","author":"Fallico","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/1874364101610010103","article-title":"Serial intravitreal bevacizumab injections slow the progression of radiation maculopathy following iodine-125 plaque radiotherapy","volume":"10","author":"Stacey","year":"2016","journal-title":"Open Ophthalmol J"},{"key":"10.1016\/j.drudis.2025.104496_b1235","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ophtha.2013.08.039","article-title":"Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma","volume":"121","author":"Shah","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.drudis.2025.104496_b1240","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/eye.1990.93","article-title":"Fluorescein angiographic features, natural course and treatment of radiation retinopathy","volume":"4","author":"Amoaku","year":"1990","journal-title":"Eye"},{"key":"10.1016\/j.drudis.2025.104496_b1245","doi-asserted-by":"crossref","first-page":"596","DOI":"10.5301\/ejo.5000940","article-title":"Intravitreal dexamethasone implant (Ozurdex\u00ae) for exudative retinal detachment after proton beam therapy for choroidal melanoma","volume":"27","author":"Malcl\u00e8s","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1250","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.survophthal.2007.06.004","article-title":"Triamcinolone acetonide in ocular therapeutics","volume":"52","author":"Jermak","year":"2007","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ajo.2016.04.024","article-title":"Antiangiogenic or corticosteroid treatment in patients with radiation maculopathy after proton beam therapy for uveal melanoma","volume":"168","author":"Seibel","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.drudis.2025.104496_b1260","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/IAE.0000000000001585","article-title":"Dexamethasone intravitreal implant vs ranibizumab in the treatment of macular edema secondary to brachytherapy for choroidal melanoma","volume":"38","author":"Russo","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.drudis.2025.104496_b1265","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00018-021-04111-2","article-title":"Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy","volume":"79","author":"Dai","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.drudis.2025.104496_b1270","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1158\/1078-0432.CCR-07-5287","article-title":"Pathways mediating resistance to vascular endothelial growth factor\u2013targeted therapy","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104496_b1275","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1167\/iovs.65.11.37","article-title":"Poor response to bevacizumab correlates with higher IL-6 and IL-8 aqueous cytokines in AMD","volume":"65","author":"Connolly","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.drudis.2025.104496_b1280","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.3390\/ijms26136174","article-title":"Age-related macular degeneration: cellular and molecular signaling mechanisms","volume":"26","author":"Jiang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104496_b1285","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s42003-023-04905-z","article-title":"Vascular cell-adhesion molecule 1 (VCAM-1) regulates JunB-mediated IL-8\/CXCL1 expression and pathological neovascularization","volume":"6","author":"Kaur","year":"2023","journal-title":"Commun Biol"},{"key":"10.1016\/j.drudis.2025.104496_b1290","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1021\/acsmedchemlett.4c00053","article-title":"A potent solution for tumor growth and angiogenesis suppression via an ELR+CXCL-CXCR1\/2 pathway inhibitor","volume":"15","author":"Grytsai","year":"2024","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2025.104496_b1295","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/biom14030252","article-title":"Treatment strategies for anti-VEGF resistance in neovascular age-related macular degeneration by targeting arteriolar choroidal neovascularization","volume":"14","author":"Fu","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2025.104496_b1300","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s40123-025-01157-4","article-title":"Systemic effects of intravitreal anti-VEGF therapy: a review of safety across organ systems","volume":"14","author":"Banerjee","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.drudis.2025.104496_b1305","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.preteyeres.2018.02.002","article-title":"Neuroprotective strategies for retinal disease","volume":"65","author":"Pardue","year":"2018","journal-title":"Prog Retin Eye Res"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:05:44Z","timestamp":1780635944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625002090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":260,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1359644625002090"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104496","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic strategies targeting ocular vasculopathies: Current advances and emerging challenges","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104496","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104496"}}